In the last decade, magnetic resonance imaging has unveiled specific AD alterations at different stages of the AD pathophysiologic continuum that conform what has been established as the AD signature. To which extent MRI can detect structural changes at the preclinical asymptomatic stage of AD - the preclinical AD signature- is still an area open for exploration. Our work supports the idea that there are brain volumetric changes specific to preclinical AD subjects and defines the preclinical AD signature based on longitudinal data. While some regions show a pattern of atrophy that overlaps with the AD signature, other specific regions exhibit changes that are unique to this early asymptomatic AD stage.